Synapsin-1 Protein

Synapsin-1 Protein

Overview

<div class="infobox infobox-protein">
<table>
<tr><th colspan="2" style="background:#e8f4f8; text-align:center; font-size:1.1em;">Synapsin-1</th></tr>
<tr><td><strong>Protein Name</strong></td><td>Synapsin-1</td></tr>
<tr><td><strong>Gene Symbol</strong></td><td>[SYN1](/genes/SYN1)</td></tr>
<tr><td><strong>UniProt ID</strong></td><td>[P17600](https://www.uniprot.org/uniprot/P17600)</td></tr>
<tr><td><strong>Alternative Names</strong></td><td>Synapsin I, SYN1</td></tr>
<tr><td><strong>Protein Family</strong></td><td>Synapsin family</td></tr>
<tr><td><strong>Molecular Weight</strong></td><td>74 kDa (705 amino acids)</td></tr>
<tr><td><strong>Subcellular Localization</strong></td><td>Presynaptic terminal (synaptic vesicles)</td></tr>
<tr><td><strong>Brain Expression</strong></td><td>Exclusively neuronal, highest in hippocampus and cerebral cortex</td></tr>
</table>
</div>

Synapsin-1 is a neuronal phosphoprotein encoded by the [SYN1](/genes/SYN1) gene that regulates synaptic vesicle clustering, mobilization, and neurotransmitter release at presynaptic terminals[@greengard1993]. It is the most extensively studied member of the synapsin family (synapsin-1 through -3 in mammals) and serves as a canonical marker of synaptic integrity. Synapsin-1 is widely used as a synaptic biomarker in cerebrospinal fluid (CSF) for neurodegenerative diseases, where elevated or reduced levels reflect synaptic pathology[@bhattacharya2022].

Structure

Synapsin-1 Protein

Overview

<div class="infobox infobox-protein">
<table>
<tr><th colspan="2" style="background:#e8f4f8; text-align:center; font-size:1.1em;">Synapsin-1</th></tr>
<tr><td><strong>Protein Name</strong></td><td>Synapsin-1</td></tr>
<tr><td><strong>Gene Symbol</strong></td><td>[SYN1](/genes/SYN1)</td></tr>
<tr><td><strong>UniProt ID</strong></td><td>[P17600](https://www.uniprot.org/uniprot/P17600)</td></tr>
<tr><td><strong>Alternative Names</strong></td><td>Synapsin I, SYN1</td></tr>
<tr><td><strong>Protein Family</strong></td><td>Synapsin family</td></tr>
<tr><td><strong>Molecular Weight</strong></td><td>74 kDa (705 amino acids)</td></tr>
<tr><td><strong>Subcellular Localization</strong></td><td>Presynaptic terminal (synaptic vesicles)</td></tr>
<tr><td><strong>Brain Expression</strong></td><td>Exclusively neuronal, highest in hippocampus and cerebral cortex</td></tr>
</table>
</div>

Synapsin-1 is a neuronal phosphoprotein encoded by the [SYN1](/genes/SYN1) gene that regulates synaptic vesicle clustering, mobilization, and neurotransmitter release at presynaptic terminals[@greengard1993]. It is the most extensively studied member of the synapsin family (synapsin-1 through -3 in mammals) and serves as a canonical marker of synaptic integrity. Synapsin-1 is widely used as a synaptic biomarker in cerebrospinal fluid (CSF) for neurodegenerative diseases, where elevated or reduced levels reflect synaptic pathology[@bhattacharya2022].

Structure

Synapsin-1 is a 705-amino acid phosphoprotein with a modular domain architecture:

| Domain | Amino Acids | Function |
|--------|-------------|---------|
| Domain A (N-terminal) | 1-120 | Membrane-binding, synaptic vesicle association via lipid interactions |
| Domain B (linker) | 120-280 | Flexible region; contains Ser9 (PKA site) |
| Domain C | 280-420 | ATP-binding site (binds ATP with high affinity); critical for vesicle clustering |
| Domain D (linker) | 420-520 | Flexible linker region |
| Domain E (C-terminal) | 520-705 | Protein-protein interactions, targets synapsin to synaptic vesicles |

ATP Binding and Regulation

Domain C contains a conserved ATP-binding cassette (ABC) fold. ATP binding induces a conformational change that increases synapsin's affinity for synaptic vesicles, promoting clustering. ATP hydrolysis releases synapsin from vesicles, allowing vesicle mobilization for release. This ATP-dependent cycling is the basis for synapsin's activity-dependent regulation of vesicle availability[@cesca2010].

Phosphorylation Sites

Synapsin-1 is phosphorylated at multiple sites that regulate its function:

| Kinase | Site(s) | Effect on Function |
|--------|---------|-------------------|
| Protein Kinase A (PKA) | Ser9 | Reduces membrane binding, promotes vesicle release |
| CaMKII | Ser603 (major), Ser566 | Dissociates synapsin from vesicles, mobilizes release-ready vesicles |
| MAPK/ERK | Multiple sites | Activity-dependent regulation |
| CDK5 | Ser549 | Modulates synaptic vesicle dynamics |
| PKC | Ser139, Ser9 | Context-dependent regulation |

Normal Function

Synaptic Vesicle Clustering

During development and in mature neurons, synapsin-1 is the primary organizer of the synaptic vesicle pool at presynaptic terminals:

This system ensures that not all vesicles are released simultaneously — synapsin maintains a releasable reserve that can be mobilized during sustained or high-frequency activity[@fornasiero2010].

Neurotransmitter Release

Synapsin-1 modulates multiple aspects of neurotransmitter release:

• Vesicle recruitment: Phosphorylated synapsin mobilizes vesicles from the reserve pool to the readily releasable pool
• Release probability: Synapsin-1 deletion reduces the size of the readily releasable pool
• Recovery after release: Synapsin-1 helps recycle vesicles back into the cluster
• Spontaneous release: Synapsin-1 also regulates spontaneous (action potential-independent) release

Synapse Formation and Maintenance

During neuronal development:

• Synapsin-1 is expressed early and guides axon pathfinding
• It promotes assembly of synaptic vesicle clusters at nascent synapses
• It maintains synaptic stability in mature neurons

Biomarker Value

Synapsin-1 is released into CSF when synapses are damaged, making it a direct measure of synaptic loss. CSF synapsin-1 levels correlate with:

• Cognitive decline in Alzheimer's disease
• Motor symptoms in Parkinson's disease
• Disease progression in ALS and frontotemporal dementia[@bhattacharya2022]

Role in Neurodegenerative Diseases

Alzheimer's Disease

Synapsin-1 dysfunction is among the earliest features of AD:

Synaptic loss as the strongest correlate:

• Synapsin-1 protein levels are significantly reduced in AD hippocampus and cortex
• Synaptic loss correlates better with cognitive decline than amyloid or tau pathology
• Synapsin-1 loss precedes neuronal death in AD models

• Aβ oligomers disrupt synaptic vesicle cycling, causing compensatory increases in synapsin-1
• In advanced AD, synapsin-1 is dramatically depleted
• Synapsin-1 is used as a synaptic outcome measure in AD drug trials

• CSF synapsin-1 is elevated in early AD (reflecting synaptic damage)
• Normalizes in advanced stages as the synaptic reservoir is exhausted
• Used in combination with Aβ and tau biomarkers for AD diagnosis

Parkinson's Disease

Dopaminergic synapse dysfunction:

• Synapsin-1 regulates vesicle release at dopaminergic synapses in the striatum
• Synapsin-1 alterations contribute to dysregulated dopamine signaling
• Alpha-synuclein (Lewy body component) interacts with synapsin-1 to regulate vesicle release

• Dopaminergic neurons in the substantia nigra have high synaptic activity, making them vulnerable to synapsin-1 dysfunction
• Synapsin-1 is a target for neuroprotective strategies in PD

Epilepsy

SYN1 mutations are associated with epilepsy in humans and animal models[@porton2021]:

• Missense mutations disrupt synapsin-1 phosphorylation
• Synapsin-1 knockout mice exhibit spontaneous seizures
• Dysregulated synaptic release contributes to hyperexcitability

Amyotrophic Lateral Sclerosis

Synapsin-1 alterations have been reported in ALS:

• Motor neuron synaptic dysfunction
• Reduced synapsin-1 at the neuromuscular junction
• Used as a synaptic outcome marker in ALS clinical trials

Therapeutic Implications

Gene Therapy Approaches

AAV-mediated synapsin-1 delivery is under investigation for neurodegenerative diseases[@bhutani2022]:

• AAV vectors with synapsin promoter drive neuron-specific expression
• Synapsin-1 overexpression can enhance synaptic function
• Potential for restoring synaptic resilience in early-stage AD/PD

Biomarker Development

CSF synapsin-1 is established as a synaptic biomarker[@bhattacharya2022]:

• Available as a clinical assay
• Used in AD research and clinical trials
• Combined with Aβ42, total tau, and phospho-tau for comprehensive AD diagnosis

Small Molecule Modulators

| Approach | Mechanism | Development Status |
|----------|-----------|-------------------|
| Kinase modulators | Enhance synapsin-1 phosphorylation | Research |
| Synaptic vesicle stabilizers | Preserve vesicle pools | Preclinical |
| Synapsin-1 replacement | AAV gene therapy | Preclinical |

Animal Models

• Synapsin-1 knockout mice: Viable but exhibit seizures, learning deficits, and impaired synaptic plasticity
• Synapsin-1/2 double knockouts: Severe neurological phenotypes, reduced survival, dramatic synaptic vesicle pool depletion
• Synapsin-1 conditional knockouts: Reveal region-specific functions

Key Publications

See Also

• [SYN1 Gene](/genes/SYN1) — The gene encoding Synapsin-1
• [Synapsin-2 Protein](/proteins/synapsin-2-protein) — Synapsin isoform
• [Synaptic Dysfunction Pathway](/mechanisms/synaptic-dysfunction-pathway) — Synaptic failure in neurodegeneration
• [Alzheimer's Disease](/diseases/alzheimers-disease) — AD and synaptic loss
• [Parkinson's Disease](/diseases/parkinsons-disease) — PD pathogenesis
• [Amyotrophic Lateral Sclerosis](/diseases/amyotrophic-lateral-sclerosis) — ALS mechanisms

External Links

• [UniProt: Synapsin-1 (P17600)](https://www.uniprot.org/uniprot/P17600)
• [NCBI: SYN1 Gene](https://www.ncbi.nlm.nih.gov/gene/6853)
• [GeneCards: SYN1](https://www.genecards.org/cgi-bin/carddisp.pl?gene=SYN1)